-
公开(公告)号：US20240299565A1
公开(公告)日：2024-09-12
申请号：US18502473
申请日：2023-11-06
CPC分类号： A61K47/6415 , A61K9/0043 , A61K9/007 , A61K38/21 , A61K38/27 , A61K47/65
摘要： The present disclosure relates to isolated non-naturally occurring delivery constructs comprising a bacterial toxin-derived delivery construct coupled to a biologically active therapeutic cargo; wherein the delivery construct is capable of delivering the biologically active cargo via transcytosis transport across an epithelial cell; and wherein the delivery construct does not comprise a bacterial toxin-derived translocation domain or a bacterial toxin-derived catalytic (cytotoxic) domain.
-
公开(公告)号：US20240197844A1
公开(公告)日：2024-06-20
申请号：US18589494
申请日：2024-02-28
申请人： AFFIRIS CVD GMBH
发明人： Sylvia BRUNNER , Gergana GALABOVA , Gabriele WINSAUER , Erika BILCIKOVA , Claudia JUNO , Pola LINZMAYER-HIRT , Birgit SCHUH , Guenther STAFFLER
IPC分类号： A61K39/00 , A61K39/385 , A61K39/39 , A61K47/64 , C12N9/64
CPC分类号： A61K39/0005 , A61K39/385 , A61K39/39 , A61K47/6415 , A61K47/643 , A61K47/646 , C12N9/6424 , C12N9/6454 , C12Y304/21061 , A61K2039/55505 , A61K2039/6081
摘要： The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.
-
公开(公告)号：US20240190990A1
公开(公告)日：2024-06-13
申请号：US18513255
申请日：2023-11-17
发明人： Liang QU , Zhuo LI , Liu XUE , Qi LIU , Lin ZHU , Penghao WANG , Hanzi SUN , Xiaoyan TANG
CPC分类号： C07K16/3007 , A61K45/06 , A61K47/6415 , A61P35/00 , A61K2039/505 , C07K2317/52 , C07K2317/732 , C07K2317/734
摘要： The present disclosure provides for antibodies and antigen-binding fragments thereof that bind to human CEA, a pharmaceutical composition comprising said antibody, and use of the anti-CEA antibody or the composition for treating a disease, such as cancer.
-
公开(公告)号：US20240115727A1
公开(公告)日：2024-04-11
申请号：US16669191
申请日：2019-10-30
发明人： Matthew J. Lazzara , Benjamin Purow , Evan K. Day
CPC分类号： A61K47/6901 , A61K47/6415 , A61P35/00 , C07K14/035 , C07K14/39 , C12N15/86 , C12Y207/01021 , C12Y305/04001
摘要： Disclosed are compositions and methods for treating a disease or disorder such as cancer in a subject in need thereof. In some aspects, the method comprises administering to the subject a vector comprising a first nucleic acid sequence encoding a promoter operably linked to each of a second nucleic acid sequence encoding a therapeutic polypeptide, and a third nucleic acid sequence encoding a peptide domain that is stabilized when phosphorylated by kinase activity in a target tissue. The kinase activity can be elevated extracellular regulated kinase (ERK) activity.
-
公开(公告)号：US20240082412A1
公开(公告)日：2024-03-14
申请号：US18503294
申请日：2023-11-07
CPC分类号： A61K47/646 , A61K39/0258 , A61K47/02 , A61K47/20 , A61K47/26 , A61K47/6415 , A61K47/65 , C08B37/0063 , A61K2039/55583
摘要： Compositions and methods for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) are described. In particular, multivalent vaccines containing O-antigen polysaccharide covalently bound to an exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein that can withstand multiple environmental stresses are describe.
-
公开(公告)号：US20240009316A1
公开(公告)日：2024-01-11
申请号：US18052455
申请日：2022-11-03
发明人： Randall J. Mrsny , Charles Olson , Sally Postlethwaite , Thomas Carl Hunter , Tahir Mahmood , Weijun Feng
IPC分类号： A61K47/64 , C07K14/195 , A61K39/02
CPC分类号： A61K47/6415 , C07K14/195 , A61K39/107
摘要： The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.
-
公开(公告)号：US20240002547A1
公开(公告)日：2024-01-04
申请号：US18348229
申请日：2023-07-06
申请人： AEBI LTD.
发明人： llan MORAD , Hanan ITZHAKI
IPC分类号： C07K17/08 , C07K14/82 , A61K47/60 , A61P35/00 , C07K14/47 , C07K7/08 , A61K47/62 , A61K47/64 , C07K14/33 , C07K14/705
CPC分类号： C07K17/08 , C07K14/82 , A61K47/60 , A61P35/00 , C07K14/4748 , C07K7/08 , A61K47/62 , A61K47/6415 , C07K14/33 , C07K14/70532 , C07K2319/33 , C07K2319/00 , C07K2319/40 , C07K2319/55 , A61K38/00
摘要： The present invention provides constructs comprising a plurality of peptides capable of targeting at least two different extracellular tumor antigens and a toxin, optionally connected to an organic scaffold. Use of such constructs in treating cancer are provided as well. The invention also provides particular peptides binding certain extracellular tumor antigens as well as toxins having antitumor activity.
-
8.发明授权公开(公告)号：US11759511B2
公开(公告)日：2023-09-19
申请号：US17848468
申请日：2022-06-24
发明人： Richard J. Porambo , Chitrananda Abeygunawardana , Luwy Kavuka Musey , Michael J. Kosinski , Yadong Adam Cui
IPC分类号： A61K39/09 , A61K47/64 , A61K47/54 , A61P37/04 , A61K39/39 , A61K47/02 , A61K47/22 , C08B37/00 , A61K39/00
CPC分类号： A61K39/092 , A61K39/39 , A61K47/02 , A61K47/22 , A61K47/549 , A61K47/646 , A61K47/6415 , A61P37/04 , C08B37/0003 , A61K2039/55505 , A61K2039/6037 , A61K2039/70
摘要： The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.
-
9.发明公开公开(公告)号：US20230211001A1
公开(公告)日：2023-07-06
申请号：US18018238
申请日：2021-07-30
CPC分类号： A61K47/6425 , A61K47/6415 , A61P35/00
摘要： Provided are bifunctional molecules that include a first moiety that specifically binds a cell surface molecule, and a second moiety that specifically binds a lysosomal targeting molecule. In certain embodiments, the first moiety is a knottin peptide comprising an engineered loop that binds to the cell surface molecule. The bifunctional molecules find use, e.g., for targeted degradation of cell surface molecules (e.g., proteins) via the endosomal/lysosomal pathway. Also provided are compositions and kits that include the bifunctional molecules, as well as methods of using the bifunctional molecules. Methods of making bifunctional molecules are also provided.
-
公开(公告)号：US20230144799A1
公开(公告)日：2023-05-11
申请号：US17934896
申请日：2022-09-23
申请人： BicycleTx Limited
CPC分类号： A61K47/6415 , A61P35/00 , A61K47/65 , A61K38/10 , A61K38/05 , A61K47/62 , C07K7/08 , A61K47/64
摘要： The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).
-
-
-
-
-
-
-
-
-
搜索结果
723 条记录 (耗时 0.028 秒)
